Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5841173 | 0.86 | POLB (0.59) | SMN1; SMN2HTTLMNAALDH1A1POLB | |
| SCHEMBL17184642 | 0.80 | POLB (0.59) | SMN1; SMN2HTTLMNAALDH1A1POLB | |
| SCHEMBL29941474 | 0.76 | POLB (0.73) | SMN1; SMN2HTTLMNAALDH1A1POLB | |
| SCHEMBL5843795 | 0.74 | ALDH1A1 (0.65) | SMN1; SMN2HTTLMNAALDH1A1 | |
| SCHEMBL5843404 | 0.74 | ALDH1A1 (0.68) | SMN1; SMN2ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL16131376 | 0.74 | RAB9A (0.60) | SMN1; SMN2ALDH1A1POLBRAB9AKMT2A | |
| SCHEMBL1030609 | 0.73 | FAAH (0.44) | LMNAALDH1A1GAAKDM4E | |
| SCHEMBL30188537 | 0.73 | FAAH (0.44) | LMNAALDH1A1GAAKDM4E | |
| SCHEMBL16695260 | 0.73 | ALDH1A1 (0.49) | ALDH1A1GAARAB9AKMT2AMEN1 | |
| SCHEMBL16695158 | 0.73 | ALDH1A1 (0.49) | ALDH1A1GAARAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067549-B2 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192292-A1 | Pyrrolidone carboxamides | NPY1R, NPY5R, NPY2R | SMN1; SMN2 3678/4885HTT 607/4885LMNA 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.